• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Novelion CEO leaves Nordisk board due to potential conflict of interest | Personnel Moves – May 16, 2017

May 16, 2017 By Sarah Faulkner

Novo NordiskNovo Nordisk (NYSE:NVO) said this week that the CEO of Canadian biotech Novelion Therapeutics, Mary Szela, left Nordisk’s board effective immediately due to a “potential conflict of interest”.

Szela’s departure follows Novelion’s decision to expand into non-alcoholic steatohepatitis, also known as fatty liver, according to a Nordisk spokeswoman. As the Danish drugmaker faces increasing pricing pressure to its core insulin business, Nordisk is looking to diversity beyond diabetes and NASH is reportedly an area of interest.

NASH, a progressive liver disease, is common in nations with rising rates of obesity and diabetes.

Nordisk hopes to use its next-gen GLP-1 drug semaglutide to treat diabetes, obestiy and NASH.

The company’s new CEO Lars Fruergaard Jorgensen has said he would consider acquisitions in the “low single-digit billions of dollars” as Nordisk diversifies into disease areas connected to diabetes.

Shares in Nordisk rose earlier this month after the insulin-maker met expectations on Wall Street with its 1st quarter results.

The company posted profits of $1.49 billion, or 60¢ per share, on sales of $4.18 billion for the 3 months ended March 31, for bottom-line growth of 7% on sales growth of 5% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were 60¢, ahead of consensus on The Street, where analysts were looking for sales of $4.09 billion.

Material from Reuters was used in this report. 

 Inhaled drug-maker Genoa names CEO, CSO
Genoa Pharmaceuticals said this week that Dr. Bruce Montgomery was named chief executive of the company and plans to lead clinical development out of the Seattle office. The company also said founder & inventor, Mark Surber, was named chief scientific officer.

The biopharmaceutical company, which raised $62 million in a Series A round this week, is developing an inhaled treatment for idiopathic pulmonary fibrosis and other severe pulmonary diseases. Genoa’s lead program, Aerodone, is slated to enter clinical development by the end of 2017.
Read more

 Pulmatrix appoints chief biz officer
Pulmatrix (NSDQ:PULM) named Ted Raad as its chief business officer to provide strategic business input as the company advances its inhaled respiratory therapies through clinical development and partnerships.

“Ted is a proven leader in the commercial development of products with significant experience in respiratory indications and infectious diseases. His vision and skill set are perfectly suited to advance our pipeline products built around our proprietary iSPERSE inhaled dry powder technology,” CEO Robert Clarke said. “His later stage and commercial experience on asthma/COPD and anti-infective drugs is a perfect complement to the R&D and development expertise of the Pulmatrix team. We’re looking forward to Ted helping us build an integrated company that will bring needed therapies to patients and opportunities for investors.”
Read more

 BioPact co-founder retakes corner office
BioPact co-founder Kent Phelps resumed his role as CEO after Joe Dillon served in the corner office for 18 months.

“The talent, experience and consummate professionalism Joe Dillon brought to BioPact will have a lasting impact on the company’s future. I think we will look back on Joe’s tenure as the tipping point for BioPact and its drug delivery platform, MGMR,” Phelp said.
Read more

 Insurance industry vet joins Lilly’s public affairs team
Eli Lilly (NYSE:LLY) said this month that the American Insurance Association’s president, Leigh Ann Pusey, will lead the company’s lobbying and public affairs efforts, effective June 12.

“Leigh Ann brings a wealth of public affairs leadership experience to Lilly and at a particularly important time for our industry,” CEO David Ricks said. “Her ability to convene conversations and drive proactive policy solutions will be critical in our efforts to promote and sustain medical innovation so patients and the health care system benefit from a new era of medicine.”
Read more

 Audentes promotes Gray to CSO
Audentes Therapeutics (NSDQ:BOLD) promoted John Gray to senior VP and chief scientific officer. Previously, Gray served as VP of R&D for the gene therapy developer.

 Before joining Audentes in 2014, he was the assistant director of the Harvard Gene Therapy Initiative.
Read more

  • Smith named VP of global clinical development ops at Graybug Vision
  • Sanofi Genzyme exec departs for Intercept Pharmaceuticals
  • Eagle Pharmaceuticals names chief financial officer
  • Formation Biologics appoints Tolcher to board

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: audentestherapeutics, BioPact, Eli Lilly & Co., genoapharmaceuticals, Novo Nordisk, Pulmatrix Inc.

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS